News

Enlarge image

FundingDenmarkNorway

Alliance for new antibiotics

27.02.2013 - Xellia Pharmaceuticals and the Statens Serum Institute have kicked-off a collaboration to find new medicines against antibiotic-resistant bacteria.

The 4 -year collaboration of the Norwegian firm with Trondheim-based SINTEF Materials and Chemistry  and the Danish Institute (Copenhagen) focusses on developing novel antibiotics to combat multi-drug resistant (MDR), Gram-negative bacteria. Supported with US$3m from the Research Council of Norway, it will target Pseudomonas, Klebsiella, Acinetobacter and Enterobacter species.

Severe sepsis and septic shock due to such infections claim up to 135,000 lives each year in Europe and 215,000 in the US. Resistance to existing antibiotics has become a major healthcare issue worldwide. In the EU alone, infections due to serious hospital-based MDR infections have been reported to cost between €28,500 and €70,100 per surviving patient.

Recently, pan-drug resistant (PDR) and even so-called extensively drug resistant (XDR) Gram-negative bacteria have started to appear, taking the treatment situation to a critical point. The lack of novel antibiotics is significantly compromising the survival and recovery of patients suffering from these infections. At present, only two antibiotic subclasses are still available to treat XDR infections, polymyxins and tigecycline. They have been used for 60-70 years without developing a significant resistance. However, these antibiotics are known to exhibit elevated nephrotoxicity (affecting kidney function) and are, therefore, not ideal for systemic treatment of XDR-infections.

Xellia aims at developing new, polymyxin-like drugs with fewer side-effects. The SINTEF and Statens Serum Institut research groups are specialists in fermentation development and drug testing. Xellia already markets four antibiotics targeting Gram-negative bacteria.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/alliance-for-new-antibiotics.html

FinancingUK

23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.

R&DDenmark

19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.

ResearchUKEU

17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).

Stock marketsGermany

15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).

LicensingDenmark

11.08.2016 Danish Genmab AS has granted Gilead Sciences license to use its DuoBody technology platform to develop bispecific antibodies for the treatment of HIV. The deal is worth up to €252m.

Clinical developmentHungaryIreland

09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.

ImmunotherapySpain

08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.

ApprovalEU

04.08.2016 After a two-year pilot period, the EMA has published its report on its adaptive pathways approach. The agency plans to “explore the concept further” and will continue to accept proposals.

BusinessPolandUK

01.08.2016 Life science venture capital group Epidarex has launched Nodthera Ltd, a biotech based on research by Poland-based drug discovery company Selvita. The start-up aims to develop novel inhibitors of the NLRP3 inflammasome.

R&DUKIreland

29.07.2016 GlaxoSmithKline has in-licensed Janssen’s anti-IL-33R monoclonal antibody for severe asthma. The British drugmaker is paying €208m up front for the mAb.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLMED (I)0.39 EUR11.43%
  • CERENIS THERAPEUTICS HOLDING SA (F)7.51 EUR10.77%
  • SYNGENTA (CH)421.20 CHF10.61%

FLOP

  • RENEURON (UK)2.62 GBP-9.03%
  • BIONOR PHARMA (N)0.48 NOK-7.69%
  • ZEALAND PHARMA (DK)113.50 DKK-6.58%

TOP

  • DIAMYD MEDICAL -B- (S)7.15 SEK70.2%
  • KARO BIO (S)37.80 SEK31.7%
  • NEUROVIVE PHARMACEUTICAL AB (S)5.80 SEK25.0%

FLOP

  • BIONOR PHARMA (N)0.48 NOK-21.3%
  • NOVOZYMES (DK)286.90 DKK-13.5%
  • RENEURON (UK)2.62 GBP-12.7%

TOP

  • KARO BIO (S)37.80 SEK2420.0%
  • NICOX (F)10.12 EUR459.1%
  • SAREUM HOLDINGS (UK)0.76 GBP261.9%

FLOP

  • BB BIOTECH (D)45.12 EUR-81.0%
  • EVOCUTIS (UK)0.04 GBP-78.9%
  • NOVACYT (F)1.29 EUR-70.6%

No liability assumed, Date: 23.08.2016